| Bioactivity | Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion[1]. |
| Invitro | Teneliximab (Chi220, BMS-224819) 的作用不仅仅是通过清除CD20承载细胞介导的，联合治疗没有显著损害已建立的抗病毒免疫[2]。 |
| Name | Teneliximab |
| CAS | 299423-37-3 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Maria A Argiriadi, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [2]. Andrew B Adams, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005 Jan 1;174(1):542-50. |